Supervisor of 64 diploma and master theses.
Supervisor of Ph. D. thesis: SCHWEIGER, Ana, 1995-1999, PREMZL, Aleš 1998-2003, FAN, Xiao-Hui, 1999 – 2002, ZAVAŠNIK-BERGANT, Tina, 1999-2003, LANGERHOLC, Tomaž, 2004-2007, OBERMAJER, Nataša, 2004-2008, JEVNIKAR, Zala, 2007-2010, MIRKOVIĆ, Bojana, 2008-2011, ROJNIK, Matija, 2008-2012, MAGISTER, Špela, 2009-2012, PIŠLAR, Anja, 2010-2013, TORKAR, Ana, 2010-2014, PEČAR FONOVIĆ, Urša, 2009-2015, VIŽIN Tjaša, 2011-2015, ŽURGA, Simon, 2011-2015, MITROVIĆ Ana, 2012-2017,PRUNK, Mateja, 2014-2018, JAKOŠ, Tanja, 2015-2020, SENJOR Emanuela 2016 -2022, CEGNAR Mateja, 2002-2005, co-supervisor, RESMAN Nuša, 2007-2010, co-supervisor, KUŽNIK Alenka, 2008-2011, co-supervisor
Prof. Janko Kos is involved in basic and translational studies of proteolytic enzymes and their inhibitors. He has been studying their role in processes leading to development and progression of cancer, immune disorders and neurodegenerative diseases. His translational research was focused on the development of new diagnostics for application in oncology and in screening, design and evaluation of various types of protease inhibitors to be used in therapy. In recent years he is developing nanoscale drug delivery systems for active targeting of tumor cells.
Scientific papers and book chapters: 300
Papers in journals with SCI: 265
Patents and patent applications: 10
Citations: >10.000 (WoS)
h-index: 56 (WoS), 68 (Google Scholar) Invited lectures 69
Honours and Awards:
Selected publications (30 from 300 scientific papers and book chapters):
BODE, W., ENGH, R. A., MUSIL, D., THIELE, U., HUBER, R., KARSHIKOV, A., BRZIN, J, KOS, J. and TURK, V. (1988):The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J.. 7, 2593-2599.
KOS, J., ŠTABUC, B., SCHWEIGER, A., KRAŠOVEC, M., CIMERMAN, N., KOPITAR-JERALA, N., VRHOVEC, I. (1997) Cathepsin B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin. Cancer Res.. 3, 1815-1822.
FOEKENS, J.A., KOS, J., PETERS, H.A., KRAŠOVEC, M., LOOK, M.P., CIMERMAN, N., MEIJER-VAN GELDER, M.E., HENZEN-LOGMANS, S.C., VAN PUTTEN, W.L.J., KLIJN, J. G.M. (1998): Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16, 1013-1021.
KOS, J. and LAH T.T.(1998): Cysteine proteinases and their endogenous inhibitors : target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncol. Rep. 5, 1349-1361.
KOS, J., ŠTABUC, B., CIMERMAN, N., BRÜNNER, N.(1998): Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin. Chem. 44, 2556-2557.
KOS, J., NIELSEN, H-J, KRAŠOVEC, M, CHRISTENSEN, IJ, CIMERMAN, N, STEPHENS, R W., BRÜNNER, N. (1998) Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res, 4, 1511-1516.
KOS, J., KRAŠOVEC, M., CIMERMAN, N., NIELSEN, H.-J., CHRISTENSEN, I.J., BRÜNNER, N. (2000): Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer : relation to prognosis. Clin. Cancer Res. 6, 505-511.
KOS, J, SEKIRNIK, A., KOPITAR, G., CIMERMAN, N., KAYSER, K., STREMMER, A., FIEHN, W., WERLE, B (2001). Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer : relation to prognosis. Br. J. Cancer 85, 8, 1193-1200
TURK, V., KOS, J., TURK, B. (2004) Cysteine cathepsins (proteases) - on the main stage of cancer?. Cancer Cell 5, 409-410.
ZAVAŠNIK-BERGANT, T., REPNIK, U., SCHWEIGER, A., ROMIH, R., JERAS, M., TURK, V., KOS, J. (2005) Differentiation- and maturation-dependent content, localization, and secretion of cystatin C in human dendritic cells. J.Leukoc. Biol., 78, 122-134.
STROJAN, P, ANIČIN, A, SVETIC, B, POHAR, M, ŠMID, A, KOS, J. (2007) Stefin a and stefin B : markers for prognosis in operable squamous cell carcinoma of the head and neck. (2007) Int. J. Radiat. Oncol. 68, 1335-1341.
KOCBEK, P., OBERMAJER, N., CEGNAR, M., KOS, J., KRISTL, J.. (2007) Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control.Rrelease, 1-2, 120, 18-26.
JEVNIKAR, Z., OBERMAJER, N., BOGYO, M., KOS, J. (2008) The role of Cathepsin X in the aggregation, Migration and invasiveness of T lymphocytes. J. Cell Science, 121, str. 2652-2661.
OBERMAJER, N., JEVNIKAR, Z., DOLJAK, B., SADAGHIANI, A. M., BOGYO, M., KOS, J. (2009). Cathepsin X-mediated ß2 integrin activation results in nanotube outgrowth. Cell Mol Life Sci 66, 1126-1132.
JEVNIKAR, Z., OBERMAJER, N., PEČAR FONOVIĆ, U., KARAOGLANOVIC-CARMONA, A., KOS, J.(2009). Cathepsin X cleaves the ß2 cytoplasmic tail of LFA-1 inducing the intermediate affinity form of LFA-1 and [alpha]-actinin-1 binding. Eur J Immunol, 2009, 39, 3217-3227.
COLIN, C., VOUTSINOS-PORCHE, B., NANNI, I., FINA, F., METELLUS, P., INTAGLIATA, D., BAEZA, N., BOUVIER, C., DELFINO, C., LOUNDOU, A., CHINOT, O., LAH TURNŠEK, T., KOS, J., MARTIN, P.M, OUAFIK, L'H., FIGARELLA-BRANGER, D. (2009) High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathologica 118, 745-754.
TAVANO, R., SEGAT, D., REDDI, E., KOS, J., ROJNIK, M., KOCBEK, P., IRATNI, S., SCHEGLMANN, D., COLUCCI, M., RIO ECHEVARRIA, I.M., SELVESTREL, F., MANCIN, F., PAPINI, E. (2010). Procoagulant properties of bare and highly PEGylated vinyl-modified silica nanoparticles. Nanomedicine, 5, 6, 881-896.
OBERMAJER, N., DOLJAK, B, POHLEVEN, J., KOS, J. (2010). A dodecapeptide deduced from cytokeratin sequence strongly enhances uPA/tPA-mediated plasminogen activation. Br. J. Haematol. 150, 121-124.
JEVNIKAR, Z., OBERMAJER, N., DOLJAK, B., TURK, S., GOBEC, S., ŠVAJGER, U., HAILFINGER, S., THOME, M., KOS, J.. (2011). Cathepsin X cleavage of the ß2 integrin regulates talin-binding and LFA-1 affinity in T cells. J. Leukocyte Biol. 90, 1, 99-109.
ROJNIK, M., KOCBEK, P., MORET, F., COMPAGNIN, C., CELOTTI, L., BOVIS, M., WOODHAMS, J., MACROBERT, A. J., SCHEGLMANN, D., HELFRICH, W., VERKAIK, M., PAPINI, E., REDDI, E., KOS, J. (2012). In vitro and in vivo characterization of temoporfin-loaded PEGlytated PLGA nanoparticles for use in photodynamic therapy. Nanomedicine (Lond., Print), 2012, vol. 7, no. 5, str. 663-677.
JEVNIKAR, Z, MIRKOVIĆ, B., PEČAR FONOVIĆ, U., ZIDAR, N., ŠVAJGER, U., KOS, J. (2012). Three-dimensional invasion of macrophages is mediated by cysteine cathepsins in protrusive podosomes. Eur. J. Immunol. 42, 12, 3429-3441.
ERJAVEC, J., KOS, J., RAVNIKAR, M., DREO, T., SABOTIČ, J. (2012). Proteins of higher fungi - from forest to application. Trends Biotechnol. 30, 5, 259-273.
SOSIČ, I., MIRKOVIĆ, B., ARENZ, K., ŠTEFANE, B, KOS, J., GOBEC, S. (2013) Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives. J. Med. Chem. 56, 2, 521-533.
PIŠLAR, A., GLAVAN, G., OBERMAJER, N., ŽIVIN, M., SCHLIEBS, R., KOS, J. (2013). Neuroprotective role of [gama]-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. Aging Cell 12, 4, 604-614.
PIŠLAR, A, ZIDAR, N., KIKELJ, D., KOS, J. (2014) Cathepsin X promotes 6-hydroxydopamine-induced apoptosis of PC12 and SH-SY5Y cells. Neuropharmacology 82, 121-131.
KOS, J., VIŽIN, T., PEČAR FONOVIĆ, U., PIŠLAR, A. (2014). Intracellular signaling by cathepsin X: molecular mechanisms and diagnostic and therapeutic opportunities in cancer. Seminars in Cancer Biol. 31, 76-83.
MIRKOVIĆ, B., MARKELC, B., BUTINAR, M., MITROVIĆ, A., SOSIČ, I., GOBEC, S., VASILJEVA, O., TURK, B., ČEMAŽAR, M., SERŠA, G., KOS, J. (2015) Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. Oncotarget 6, 22, 19027-19042.
PIŠLAR, A., PERIŠIĆ, M., KOS, J. (2015) Lysosomal cysteine peptidases - molecules signaling tumor cell death and survival. Seminars in Cancer Biol., 34,1-12.
MITROVIĆ, Ana, ZAVRŠNIK, Janja, MIKHAYLOV, Georgy, KNEZ, Damijan, PEČAR FONOVIĆ, Urša, MATJAN-ŠTEFIN, Petra, BUTINAR, Miha, GOBEC, Stanislav, TURK, Boris, KOS, Janko. Evaluation of novel cathepsin-X inhibitors in vitro and in vivo and their ability to improve cathepsin-B-directed antitumor therapy. Cellular and molecular life sciences. 2022, 79, no. 1, 34-1-34-14.
Membership and Editorial:
Janko Kos was born in 1959 in Ljubljana, Slovenia. He received B.Sc. in chemistry at the University of Ljubljana in 1984 and M.Sc. and Ph. D. in biochemistry in 1988 and 1992, respectively, at the same university. From 1992 to 1995 he was a postdoctoral fellow at the Jozef Stefan Institute in Ljubljana, Slovenia and from 1995 to 2004 a Head of Department of Biochemical Research and Drug Design in Krka, Pharmaceutical Company. In 2004 he became an associate and in 2006 a full professor of biochemistry at the University of Ljubljana, Faculty of Pharmacy. From 2007 to 2020 he was a Head of the Department of Biotechnology at Jozef Stefan Institute. As a Ph. D. and postdoctoral fellow and as a visiting professor he was at Max Planck Institute for Biochemistry, Martinsried, Germany, Federal Cardiological Institute, Moscow, Russia, University of Sheffield, UK, and Institute of Pharmacology and Pathology of Royal Veterinary and Agriculture University, Copenhagen, Denmark. Janko Kos is involved in basic and translational studies of proteolytic enzymes and their inhibitors. He has been studying their role in processes leading to development and progression of cancer, immune disorders and neurodegenerative diseases. His translational research was focused on the development of new diagnostics for application in oncology and in screening, design and evaluation of various types of protease inhibitors to be used in therapy. In recent years he was involved also in development of nanoscale drug delivery systems. The results of his research work were published in more than 300 scientific papers and book chapters and frequently cited (>10000 citations, h index 56 - WoS, 68 Google Scholar). His applicative work resulted in several new products, 10 patents and patent applications and fruitful collaboration with industrial partners. Janko Kos is a chair of courses on biochemistry and cancer biology for undergraduate and graduate students, he was a supervisor of 21 Ph. D. students, organizer and invited lecturer at scientific conferences, editor and editorial board member and project leader of national and international projects. He was a President of Slovenian Biochemical Society from 2014 to 2021, Chair (2021 - 2023) of FEBS, member of Slovenian Chemical Society, Pathobiology Group of EORTC, International Proteolysis Society, American Nano Society and Radiology&Oncology Society. He achieved several honors and awards for scientific achievements, including Zois amendment for outstanding achievements in science from the Republic of Slovenia in 2002, Lapanje award from Slovenian Biochemical Society in 2009, the award »Supervisor of the year« from Slovenian Young Researcher Society in 2009 and Zois award for outstanding achievements in science in the field of proteolytic enzymes from the Republic of Slovenia in 2013, Lifetime Achievement Award, University of Ljubljana, Faculty of Pharmacy in 2021 and Lapanje Plaquette, Slovenian Biochemical Society in 2022. From 2015 he is a member of European Academy of Sciences and Arts (EASA).